A Nursing Perspective on PARP Inhibitors in Prostate Cancer

PCE

English - June 30, 2022 12:00 - 11 minutes - 10.7 MB - ★★★★ - 6 ratings
Courses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: An Update from ASCO 2022

Next Episode: ASCO 2022: Advances in CLL/SLL

In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include:

An overview of the PROpel study of olaparib and the TRITON study of rucaparibFDA-approved indications for olaparib and rucaparibGenetic and molecular testing for BRCA1/2 and other HRR mutationsManaging adverse events associated with olaparib and rucaparibMonitoring for and managing anemiaGastrointestinal side effectsFatigueA look at the future of PARP inhibitors in mCRPC with combination approaches of AR-directed therapy and PARP inhibition

Presenter:
Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois

Link to full program:
PCE.is/Onc22